Terms: = Ovarian cancer AND BRCA1, BRCAI, 672, ENSG00000012048, IRIS, BRCC1, RNF53, PSCP AND Staging
40 results:
1. The analysis of preoperative or intraoperative factors in predicting the escalation of surgical pathological staging of patients with clinical stage I endometrioid carcinoma: A retrospective clinical study.
Li N; Chen Q; Li B
Medicine (Baltimore); 2024 Mar; 103(11):e37465. PubMed ID: 38489719
[TBL] [Abstract] [Full Text] [Related]
2. brca1, BRCA2, and TP53 germline and somatic variants and clinicopathological characteristics of Brazilian patients with epithelial ovarian cancer.
Richau CS; Scherer NM; Matta BP; de Armas EM; de Barros Moreira FC; Bergmann A; Pereira Chaves CB; Boroni M; Dos Santos ACE; Moreira MAM
Cancer Med; 2024 Feb; 13(3):e6729. PubMed ID: 38308422
[TBL] [Abstract] [Full Text] [Related]
3. Counselling Framework for Germline
Wong SM; Apostolova C; Eisenberg E; Foulkes WD
Curr Oncol; 2024 Jan; 31(1):350-365. PubMed ID: 38248108
[TBL] [Abstract] [Full Text] [Related]
4. [Application of genetic counseling and preventive surgery in hereditary breast-ovarian cancer syndrome based on a rare family].
Liu SH; Dong L; Li B; Zhao D; Ying JM
Zhonghua Zhong Liu Za Zhi; 2023 Sep; 45(9):796-802. PubMed ID: 37805444
[No Abstract] [Full Text] [Related]
5. Management of patients with advanced epithelial ovarian cancer: a European survey.
Jochum F; Angeles MA; Balaya V; Drouin L; Nikolova T; Mathevet P; Lécuru F; Azais H; Betrian S; Bolze PA; Dabi Y; Kerbage Y; Sanson C; Zaccarini F; Guyon F; Akladios C; Hsu A; Bendifallah S; Deluche E; Guani B
Arch Gynecol Obstet; 2023 Aug; 308(2):535-549. PubMed ID: 36737552
[TBL] [Abstract] [Full Text] [Related]
6. Risk reducing surgery with peritoneal staging in brca1-2 mutation carriers. A prospective study.
Marchetti C; Arcieri M; Vertechy L; Ergasti R; Russo G; Zannoni GF; Minucci A; Ercoli A; Scambia G; Fagotti A
Eur J Surg Oncol; 2022 Dec; 48(12):2539-2544. PubMed ID: 35871032
[TBL] [Abstract] [Full Text] [Related]
7. An in-Depth Analysis of ovarian cancer: Pathogenesis and Clinical Manifestation.
Mahima M; Mahmood T; Ved A; Siddiqui MH; Ahsan F; Shamim A; Ansari VA; Ahmad A; Kashyap MK
Drug Res (Stuttg); 2022 Oct; 72(8):424-434. PubMed ID: 35760337
[TBL] [Abstract] [Full Text] [Related]
8. ovarian stimulation for fertility treatments and risk of breast cancer: a matched cohort study.
Machtinger R; Fallach N; Goldstein I; Chodick G; Schiff E; Orvieto R; Mashiach R
Hum Reprod; 2022 Mar; 37(3):577-585. PubMed ID: 34871410
[TBL] [Abstract] [Full Text] [Related]
9. Detection of brca1/2 Mutation and Analysis of Clinicopathological Characteristics in 141 Cases of ovarian cancer.
Li L; Chen F; Lin A; Wang D; Shi Y; Chen G
Comput Math Methods Med; 2021; 2021():4854282. PubMed ID: 34721658
[TBL] [Abstract] [Full Text] [Related]
10. Efficacy of risk-reducing salpingo-oophorectomy in brca1-2 variants and clinical outcomes of follow-up in patients with isolated serous tubal intraepithelial carcinoma (STIC).
Saccardi C; Zovato S; Spagnol G; Bonaldo G; Marchetti M; Alessandrini L; Tognazzo S; Guerriero A; Vitagliano A; Laganà AS; Noventa M
Gynecol Oncol; 2021 Nov; 163(2):364-370. PubMed ID: 34465478
[TBL] [Abstract] [Full Text] [Related]
11. CAMK2N1/RUNX3 methylation is an independent prognostic biomarker for progression-free and overall survival of platinum-sensitive epithelial ovarian cancer patients.
Heinze K; Rengsberger M; Gajda M; Jansen L; Osmers L; Oliveira-Ferrer L; Schmalfeldt B; Dürst M; Häfner N; Runnebaum IB
Clin Epigenetics; 2021 Jan; 13(1):15. PubMed ID: 33482905
[TBL] [Abstract] [Full Text] [Related]
12. Value of adjuvant chemotherapy and informed microscopic examination for occult gynecologic cancer detected upon risk-reducing salpingo-oophorectomy after chemotherapy for brca1/2-associated breast cancer: a case report.
Kuji S; Kondo H; Ohara T; Deura I; Tozawa-Ono A; Migita O; Kawamoto H; Tsugawa K; Chosokabe M; Koike J; Maeda I; Suzuki N
Jpn J Clin Oncol; 2021 Mar; 51(3):492-497. PubMed ID: 33377156
[TBL] [Abstract] [Full Text] [Related]
13. Association of expression of p53, livin, ERCC1, brca1 and PARP1 in epithelial ovarian cancer tissue with drug resistance and prognosis.
Zhang Z; Dou X; Yang H; Jia L; Qin K; Gao X; Yang B; Zhang W; Qin C; Zhang F; Shan B
Pathol Res Pract; 2020 Feb; 216(2):152794. PubMed ID: 31902551
[TBL] [Abstract] [Full Text] [Related]
14. Outcome and Prognostic Impact of Surgical staging in Serous Tubal Intraepithelial Carcinoma: A Cohort Study and Systematic Review.
Van der Hoeven NMA; Van Wijk K; Bonfrer SE; Beltman JJ; Louwe LA; De Kroon CD; Van Asperen CJ; Gaarenstroom KN
Clin Oncol (R Coll Radiol); 2018 Aug; 30(8):463-471. PubMed ID: 29691126
[TBL] [Abstract] [Full Text] [Related]
15. Changes in classification of genetic variants in brca1 and BRCA2.
Kast K; Wimberger P; Arnold N
Arch Gynecol Obstet; 2018 Feb; 297(2):279-280. PubMed ID: 29302806
[TBL] [Abstract] [Full Text] [Related]
16. Management of Preinvasive Lesions.
Patrono MG; Corzo C; Iniesta M; Ramirez PT
Clin Obstet Gynecol; 2017 Dec; 60(4):771-779. PubMed ID: 28957950
[TBL] [Abstract] [Full Text] [Related]
17. [Innovations in the treatment of ovarian cancer. Analysis of the therapeutic development: from platinum to immunotherapy.].
Angius G; Sepe P; Papa A; Tomao S; Tomao F
Recenti Prog Med; 2017 Jun; 108(6):269-281. PubMed ID: 28631775
[TBL] [Abstract] [Full Text] [Related]
18. Ex vivo retrieval and cryopreservation of oocytes from oophorectomized specimens for fertility preservation in a brca1 mutation carrier with ovarian cancer.
Pereira N; Hubschmann AG; Lekovich JP; Schattman GL; Rosenwaks Z
Fertil Steril; 2017 Aug; 108(2):357-360. PubMed ID: 28629583
[TBL] [Abstract] [Full Text] [Related]
19. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A
Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976
[TBL] [Abstract] [Full Text] [Related]
20. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline brca1/2 mutated patients with advanced ovarian cancer.
Rafii S; Gourley C; Kumar R; Geuna E; Ern Ang J; Rye T; Chen LM; Shapira-Frommer R; Friedlander M; Matulonis U; De Greve J; Oza AM; Banerjee S; Molife LR; Gore ME; Kaye SB; Yap TA
Oncotarget; 2017 Jul; 8(29):47154-47160. PubMed ID: 28454085
[TBL] [Abstract] [Full Text] [Related]
[Next]
